A Phase 1 interventional study of Artesunate Suppositories in HPV-Related Anal Intraepithelial Neoplasia, AIN2/3 and Artesunate, sponsored by Johns Hopkins University. Completed at 2 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-11-03.
Sponsored by Johns Hopkins University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Precancerous Conditions with a site in United States — 6 open to participants now, 12 under way, 2 of them phase 3. Precancerous Conditions · United States.
Among the 151 studies in Precancerous Conditions with a site in United States, this one is the 87th largest by enrollment of the 105 interventional ones that give a count, is one of 3 that started in 2017, is one of 26 in phase 1, and was the 138th registered.
217 studies on the registry are indexed under Precancerous Conditions; 16 are open to participants now.
Browse Precancerous Conditions studies →6 of the 151 studies in Precancerous Conditions with a site in United States are open now. Recruiting first, the newest first:
Orca Biosystems, Inc. · Sites in United States
Ages 18+
Sun Pharmaceutical Industries, Inc. · Sites in United States
Ages 18–85
Sun Pharmaceutical Industries, Inc. · Sites in United States
Ages 18–85
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Precancerous Conditions studies recruiting now, 6 (50%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 52 · Phase 3 23 · Phase 4 1
First in 1971; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 70 across 143 interventional studies indexed under Precancerous Conditions.
Median enrollment 58 across the 105 interventional studies, 302 across the 25 observational. Of the 125 that completed or were terminated, 48 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 151 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 1 study filed under Precancerous Conditions — fewer than ten, so there is no comparison to draw.
3 of the studies in Precancerous Conditions with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
Add all 3 to your calendar (.ics) → With an account.
Among the 151 studies in Precancerous Conditions with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
Patients diagnosed with AIN 2/3 will be enrolled sequentially in treatment cohorts receiving different doses of Artesunate suppositories administered trans-anally. Doses of escalation will be 200 mg, 400 mg, and 600 mg. Treatment cohorts will consist of 2 or 3 cycles at each dose level. Suppositories will be administered daily for 5 days. Five days constitutes 1 cycle. Up to 3 cycles will be administered at Weeks 0, 2, and 4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two five-day cycles of Artesunate suppositories, 200 mg/day
Drug: Artesunate Suppositories
Three five-day cycles of Artesunate suppositories, 200 mg/day
Drug: Artesunate Suppositories
Two five-day cycles of Artesunate suppositories, 400 mg/day
Drug: Artesunate Suppositories
Three five-day cycles of Artesunate suppositories, 400 mg/day
Drug: Artesunate Suppositories
Two five-day cycles of Artesunate suppositories, 600 mg/day
Drug: Artesunate Suppositories
Three five-day cycles of Artesunate suppositories, 600 mg/day
Drug: Artesunate Suppositories
Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
Also known as: Artemisinin
Incidence of treatment-emergent adverse events (Safety and tolerability) of Artesunate suppositories for the treatment of anal intraepithelial neoplasia (AIN2/3)
Number of patients with serious adverse events or dose limiting toxicities related to the study medication, according to CTCAE4.0
Time frame: 6 weeks from the date of the first dosing
Number of patients with histologic regression of anal intraepithelial neoplasia (AIN2/3) to AIN1 or less
Number of patients with no AIN2/3 as assessed by high resolution anoscopy and biopsy
Time frame: 16 weeks
Number of patients with histologic regression of anal intraepithelial neoplasia (AIN2/3) to AIN1 or less
Number of patients with no AIN2/3 as assessed by high resolution anoscopy and biopsy
Time frame: 28 weeks
Number of patients with viral clearance of human papillomavirus (HPV) virus measured by HPV genotyping
Number of patients with HPV genotypes present at study entry which become undetectable during the study window
Time frame: 40 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2017 to primary completion in Oct 2021, 53 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Artemisinin